FDA issues warning on AAA (abdominal aortic aneurysms) endovascular graft devices
This article was originally published in Clinica
Executive Summary
The US FDA is warning physicians that serious problems, such as rupture and vessel damage, have occurred with the two endovascular graft devices now on the market for treatment of abdominal aortic aneurysms (AAA). The agency has not called for any change in how Guidant's Ancure System or Medtronic's AneuRx System are used. But its April 27 public health notification recommends that doctors make sure that all implanted patients are carefully followed and receive periodic follow-up imaging.